Debiopharm
Switzerland · Biotechnology, Health Care, Therapeutics
Debiopharm is a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases. Debiopharm is focused on developing innovative therapeutic agents to outsmart hard-to-treat cancers and has a portfolio of carefully selected targets with first-in-class or best-in-class potential.
Key facts
- Headquarters
- Switzerland
- Employees
- 494
- Industries
- Biotechnology, Health Care, Therapeutics
- Website
- www.debiopharm.com
- Company page
Recent activity at Debiopharm
- : Debiopharm Partners with Genialis to Utilize AI Software for Biomarker Discovery. (date Fundz recorded it)
- : Debiopharm secured $5.76M from CARB-X to progress the preclinical development of Debio 1453, an antibiotic targeting drug-resistant Neisseria gonorrhoeae infections.
- : Debiopharm and WhiteLab Genomics Announce Strategic Partnership in Oncology (date Fundz recorded it)
- : ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs (date Fundz recorded it)
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Debiopharm funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2024 | Funding Round | $5.8M |
Leadership
- Bertrand Ducrey, Chief Executive Officer
- Angela Zubel, Chief Development Officer
Verified email and direct lines for Debiopharm’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Debiopharm in the news
- Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma - Business Wire (Oct 20, 2026)
- Debiopharm's Novel Antibiotic Advancing Against Drug-Resistant Gonorrhea - Contagion Live (Nov 20, 2025)
- Merck agrees $1 bln deal with Debiopharm for head and neck cancer drug - Reuters (Mar 01, 2021)
- FluoSphera Licenses Debiopharm’s AbYlink™ Technology for 3D Antibody Characterization while Leveraging Leica Microsystems Viventis Deep Imaging Capabilities - Business Wire (Sep 01, 2026)
- Kaiku Health Raises €4.4 Million Series A Financing to Accelerate Its Digital Therapeutics Pipeline Led by Debiopharm and Tesi - PR Newswire (Apr 05, 2018)
- Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance - Business Wire (Oct 14, 2026)
- Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research - Business Wire (Apr 24, 2025)
- Debiopharm and Alkyon Therapeutics Announce Research Collaboration to Advance the Next Generation of Radioligand Therapies - Business Wire (Jun 12, 2025)
Companies similar to Debiopharm
- Veristat · Biotechnology, Health Care, Therapeutics
- Amicus Therapeutics · Biotechnology, Health Care, Therapeutics
- Acadia Pharmaceuticals · Biotechnology, Health Care, Therapeutics
- bluebird bio · Biotechnology, Health Care, Therapeutics
- BioCryst Pharmaceuticals · Biotechnology, Health Care, Therapeutics
About Debiopharm: questions and answers
What does Debiopharm do?
Debiopharm is a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases. Debiopharm is focused on developing innovative therapeutic agents to outsmart hard-to-treat cancers and has a portfolio of carefully selected targets with first-in-class or best-in-class potential.
Where is Debiopharm headquartered?
Debiopharm is headquartered in Switzerland.
How many employees does Debiopharm have?
Debiopharm has about 494 employees.
Has Debiopharm raised funding?
Yes. Fundz has recorded 1 funding event for Debiopharm. The most recent, Funding Round of $5.8M, was in Nov 2024.
Who leads Debiopharm?
Bertrand Ducrey is a Chief Executive Officer at Debiopharm.
What is the latest news on Debiopharm?
On Jan 11, 2026, Debiopharm Partners with Genialis to Utilize AI Software for Biomarker Discovery.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy